TC 14012 |
| رقم الكتالوجGC17122 |
TC 14012 ، مشتق مصل ثابت من T140 ، هو مناهض CXCR4 انتقائي ومحاكي للببتيد مع IC50 من 19.3 نانومتر.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 368874-34-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
TC14012, a serum-stable derivative of T140, is a selective and peptidomimetic CXCR4 antagonist with an IC50 of 19.3 nM. TC14012 is a potent CXCR7 agonist with an EC50 of 350 nM for recruiting β-arrestin 2 to CXCR7. TC14012 has anti-HIV activity and anti-cancer activity [1-3].
TC14012(10-10-10-5M ; 37℃; 90 min) induce coupling of CXCR7 with β-arrestin in a dose-dependent manner in 293FT cell β-Arrestin recruitment assay[4]. In TC14012-treated(0-30µM) HUVECs(human umbilical vein endothelial cells), specific activation of CXCR7 significantly promoted the tubular formation of HUVECs[5]. TC14012 may promote osteogenesis or chondrodifferentiation in the treatment of mesenchymal stem cell (MSC) [6].
TC14012(10 mg/kg; i.p. ; 4 times every 6 days) significantly increased the left ventricular internal diameter-diastole/systole (LVID-d/s), a key cardiac structure index, and the EFFS, and left ventricular volume-diastole/systole (LV vol-d/s) in AMI mice. TC14012 reduced the infarct size and increased the vascular density in AMI model mice. TC14012 promoted angiogenesis in vivo, and TC14012 increased the levels of VWF, VEGFR2, p-SRC and p-PLC-γ as well as the p-P38/t-P38 ratio [7].
References:
[1]. Tamamura H, Omagari A, et,al. Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140. Bioorg Med Chem Lett. 2001 Jul 23;11(14):1897-902. doi: 10.1016/s0960-894x(01)00323-7. PMID: 11459656.
[2]. Gravel S, Malouf C, et,al. The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains. J Biol Chem. 2010 Dec 3;285(49):37939-43. doi: 10.1074/jbc.C110.147470. Epub 2010 Oct 18. PMID: 20956518; PMCID: PMC2992227.
[3]. Gravel S, Malouf C, et,al. The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains. J Biol Chem. 2010 Dec 3;285(49):37939-43. doi: 10.1074/jbc.C110.147470. Epub 2010 Oct 18. PMID: 20956518; PMCID: PMC2992227.
[4]. Ishizuka M, Harada M, et,al. CXCR7 ameliorates myocardial infarction as a β-arrestin-biased receptor. Sci Rep. 2021 Feb 9;11(1):3426. doi: 10.1038/s41598-021-83022-5. Erratum in: Sci Rep. 2021 Jun 7;11(1):12340. PMID: 33564089; PMCID: PMC7873251.
[5]. Zhang M, Qiu L, et,al. CXCL12 enhances angiogenesis through CXCR7 activation in human umbilical vein endothelial cells. Sci Rep. 2017 Aug 15;7(1):8289. doi: 10.1038/s41598-017-08840-y. PMID: 28811579; PMCID: PMC5557870.
[6]. Wei ST, Huang YC, et,al. Gain of CXCR7 function with mesenchymal stem cell therapy ameliorates experimental arthritis via enhancing tissue regeneration and immunomodulation. Stem Cell Res Ther. 2021 May 29;12(1):314. doi: 10.1186/s13287-021-02402-w. PMID: 34051857; PMCID: PMC8164772.
[7]. Zhang S, Yue J, et,al. Activation of CXCR7 alleviates cardiac insufficiency after myocardial infarction by promoting angiogenesis and reducing apoptosis. Biomed Pharmacother. 2020 Jul;127:110168. doi: 10.1016/j.biopha.2020.110168. Epub 2020 Apr 28. PMID: 32361166.
Average Rating: 5 (Based on Reviews and 12 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *